Top-Rated Stocks NASDAQ:JAZZ Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. $142.60 -0.75 (-0.52%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range$142.54▼$144.4050-Day Range$133.98▼$157.7752-Week Range$125.36▼$169.98Volume407,570 shsAverage Volume535,169 shsMarket Capitalization$9.03 billionP/E RatioN/ADividend YieldN/APrice Target$204.27 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Jazz Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside43.2% Upside$204.27 Price TargetShort InterestHealthy3.66% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment1.01Based on 12 Articles This WeekInsider TradingSelling Shares$2.06 M Sold Last QuarterProj. Earnings Growth15.33%From $14.68 to $16.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.88 out of 5 starsMedical Sector45th out of 1,002 stocksPharmaceutical Preparations Industry12th out of 488 stocks 3.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $204.27, Jazz Pharmaceuticals has a forecasted upside of 43.2% from its current price of $142.60.Amount of Analyst CoverageJazz Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.66% of the outstanding shares of Jazz Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 4.92%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 2.8 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Jazz Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 12 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,056,822.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.79% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 15.33% in the coming year, from $14.68 to $16.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is -40.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is -40.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 0.80. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jazz Pharmaceuticals (NASDAQ:JAZZ) StockJazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.Read More Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Stock News HeadlinesMarch 9, 2023 | marketbeat.comZymeworks Offers Hope for More than Just Long-Term Investors (JAZZ)Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higherMarch 28, 2023 | marketwatch.comMedical Asparaginase Market Share, Key Dynamics and Forecast to 2031March 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 28, 2023 | markets.businessinsider.comMore than 100 Biopharmas Increase Impactful Engagement with Veeva CRM Events ManagementMarch 28, 2023 | marketwatch.comLewy Body Dementia Treatment Market Top Players By 2031March 27, 2023 | marketwatch.comOligonucleotide Therapeutics Market | Newsest ResearchMarch 23, 2023 | marketwatch.comAsparaginase Market Growth and Forecast till 2031March 22, 2023 | marketwatch.comGlobal Asparaginase Market (2023-2029)-Opportunities for Growth and ExpansionMarch 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 21, 2023 | finance.yahoo.comMy Top Cannabis Stock to Buy in 2023 and Hold For 10 YearsMarch 19, 2023 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells $136,284.06 in StockMarch 17, 2023 | marketwatch.comClozapine Market Share and Forecast till 2028March 16, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Nuvation Bio (NUVB)March 15, 2023 | finance.yahoo.comJazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical PipelineMarch 14, 2023 | ft.comCeladon becomes first UK medical cannabis group to win right to sell in BritainMarch 14, 2023 | marketwatch.comMarine Pharmaceuticals Market Analysis: Understanding The Current State and Future Trends 2023-2028March 14, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)March 8, 2023 | finance.yahoo.comJazz Pharmaceuticals Secures Eight Additional Provincial Reimbursements for Vyxeos® for Treatment of Adults with Newly Diagnosed Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related ChangesMarch 8, 2023 | finance.yahoo.comThose who invested in Jazz Pharmaceuticals (NASDAQ:JAZZ) three years ago are up 29%March 7, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Verrica Pharmaceuticals (VRCA)March 6, 2023 | msn.comThe Latest Analyst Ratings for Jazz PharmaceuticalsMarch 6, 2023 | finance.yahoo.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Q4 2022 Earnings Call TranscriptMarch 2, 2023 | msn.comJazz Q4 2022 Revenue Grows 8% To $972M, Provides OutlookMarch 1, 2023 | finance.yahoo.comJazz Pharmaceuticals (JAZZ) Reports Q4 Loss, Misses Revenue EstimatesMarch 1, 2023 | msn.comJazz Pharmaceuticals Non-GAAP EPS of -$0.07 misses by $1.19, revenue of $972.12M misses by $3.75M, guidance in-lineMarch 1, 2023 | finance.yahoo.comJazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial GuidanceMarch 1, 2023 | finance.yahoo.comIs Jazz Pharmaceuticals 'All That' Heading Into Earnings?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Company Calendar Last Earnings11/09/2021Today3/28/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Forecast$204.27 High Stock Price Forecast$225.00 Low Stock Price Forecast$187.00 Forecasted Upside/Downside+43.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.55) Trailing P/E RatioN/A Forward P/E Ratio9.71 P/E Growth0.8Net Income$-224,060,000.00 Net Margins-6.12% Pretax Margin-10.19% Return on Equity24.04% Return on Assets6.88% Debt Debt-to-Equity Ratio1.85 Current Ratio2.79 Quick Ratio2.03 Sales & Book Value Annual Sales$3.66 billion Price / Sales2.47 Cash Flow$22.28 per share Price / Cash Flow6.40 Book Value$49.01 per share Price / Book2.91Miscellaneous Outstanding Shares63,330,000Free Float60,544,000Market Cap$9.03 billion OptionableOptionable Beta0.73 Social Links Key ExecutivesBruce C. CozaddChairman & Chief Executive OfficerDaniel N. SwisherPresidentRenée D. GaláChief Financial Officer & Executive Vice PresidentRobert IannoneExecutive Vice President-Research & DevelopmentFinbar LarkinSenior Vice President-Technical OperationsKey CompetitorsPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTHorizon Therapeutics PublicNASDAQ:HZNPDr. Reddy's LaboratoriesNYSE:RDYTeva Pharmaceutical IndustriesNYSE:TEVAView All CompetitorsInsiders & InstitutionsPatricia CarrSold 1,023 sharesTotal: $136,284.06 ($133.22/share)Victory Capital Management Inc.Sold 259,740 shares on 3/10/2023Ownership: 0.864%Kim SablichSold 3,013 sharesTotal: $421,036.62 ($139.74/share)Kenneth W O'keefeSold 2,690 sharesTotal: $372,269.10 ($138.39/share)Rockefeller Capital Management L.P.Bought 1,758 shares on 3/6/2023Ownership: 0.061%View All Insider TransactionsView All Institutional Transactions JAZZ Stock - Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks. What is Jazz Pharmaceuticals' stock price forecast for 2023? 8 brokers have issued 12-month price objectives for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they anticipate the company's share price to reach $204.27 in the next year. This suggests a possible upside of 43.2% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts. How have JAZZ shares performed in 2023? Jazz Pharmaceuticals' stock was trading at $159.31 at the beginning of the year. Since then, JAZZ shares have decreased by 10.5% and is now trading at $142.60. View the best growth stocks for 2023 here. When is Jazz Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our JAZZ earnings forecast. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $2.60 by $1.60. The specialty pharmaceutical company earned $838.12 million during the quarter, compared to analyst estimates of $829.98 million. Jazz Pharmaceuticals had a negative net margin of 6.12% and a positive trailing twelve-month return on equity of 24.04%. During the same quarter last year, the company posted $3.86 earnings per share. What ETFs hold Jazz Pharmaceuticals' stock? ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE), Amplify Seymour Cannabis ETF (CNBS), AdvisorShares Pure Cannabis ETF (YOLO), SPDR S&P Pharmaceuticals ETF (XPH), Psyk Etf (PSYK), iShares U.S. Pharmaceuticals ETF (IHE), Invesco Dynamic Pharmaceuticals ETF (PJP) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals updated its FY23 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of $16.90-$17.85 for the period, compared to the consensus estimate of $18.10. The company issued revenue guidance of $3.675-$3.875 billion, compared to the consensus revenue estimate of $3.76 billion. What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (4.53%), LSV Asset Management (3.26%), Renaissance Technologies LLC (2.05%), Franklin Resources Inc. (2.03%), Polaris Capital Management LLC (1.99%) and Geode Capital Management LLC (1.49%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $142.60. How much money does Jazz Pharmaceuticals make? Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.03 billion and generates $3.66 billion in revenue each year. The specialty pharmaceutical company earns $-224,060,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis. How many employees does Jazz Pharmaceuticals have? The company employs 2,800 workers across the globe. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850. This page (NASDAQ:JAZZ) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.